Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new biopharmaceutical client headquartered in South Korea. This new project is with a South Korean clinical stage biopharmaceutical company focused on the development of next-generation antibody drug conjugate (ADC) and Immuno-oncology therapeutic for the...
Read More